Pulmonary embolism (PE)
Conditions
Interventions
Experimental group:Percutaneous mechanical pulmonary artery thrombectomy
Sponsors
The Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1.The participant or their guardian is aware of the nature of this study, agrees to participate, and has signed the consent form. 2.Age is between 18 and 85, regardless of gender. 3.Clinically diagnosed with symptomatic acute pulmonary embolism, with CT imaging indicating right - heart dysfunction (defined as an RV/LV ratio of 0.9 or higher). 4.The investigator has assessed that the participant is suitable for intra - vascular angiography and interventional therapy.
Exclusion criteria
Exclusion criteria: 1. Target vessel diameter is less than 6mm. 2.The target lesion has serious calcification, plaque, or stenosis. 3.Systolic blood pressure is below 90mmHg, or even with sufficient filling, vasopressors are needed to keep systolic pressure at or above 90mmHg, and the patient has end - organ hypoperfusion. 4.Systolic blood pressure is below 90mmHg or drops by 40mmHg or more for over 15 minutes, and this isn't due to new arrhythmia, low blood volume, or sepsis. 5.Patients with pulmonary artery systolic pressure over 70mmHg. 6.Hematocrit is less than 28%. 7.Patients with a history of chronic pulmonary arterial hypertension. 8.Patients with left bundle branch block. 9.A history of chronic left - sided heart failure and a left ventricular ejection fraction of 30% or less. 10. Abnormal kidney function (serum creatinine above 1.8mg/dL or above 159umol/L). 11.Known coagulation problems or a bleeding tendency (INR above 3). 12.Patients who can't take anti - platelet or anticoagulant therapy. 13.Had heart or lung surgery within 7 days before the procedure. 14.A pacemaker was implanted in the right atrium or right ventricle within 6 months before the procedure. 15.Patients with blood clots in the heart. 16.Patients receiving extracorporeal membrane oxygenation. 17.Known allergy to contrast agents. 18. Diseases that may make treatment and assessment difficult. 19.Pregnant and breastfeeding women. 20.Life expectancy of less than one month. 21.Taking part in other drug or medical device clinical trials. 22.Patients whom the investigator thinks are unsuitable for the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Right ventricular end - diastolic inner diameter/left ventricular end - diastolic inner diameter (RV/LV); | — |
Countries
China
Contacts
Public ContactMeng Xiaohu
The Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine
Outcome results
None listed